Navigation Links
Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Date:11/13/2008

ISELIN, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today announced that it received notice from The Nasdaq Stock Market ("Nasdaq") on November 11, 2008 that the Company is not in compliance with Nasdaq Marketplace Rule 4310(c)(3), which requires the Company to have a minimum of $2,500,000 in stockholders' equity or $35,000,000 market value of listed securities or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. At September 30, 2008, the Company's stockholders' equity was $1,315,698, and the market value of its listed securities was $4,193,646. The Company has had net losses from its continuing operations for the three most recently completed fiscal years.

As previously disclosed, the Company is also currently not in compliance with Nasdaq Marketplace Rule 4310(c)(4), which requires that the minimum bid price per share of the Company's common stock shall be $1.

Under these circumstances, Nasdaq is reviewing the Company's eligibility for continued listing on the Nasdaq Capital Market. In order to facilitate this review, the Company intends to provide to Nasdaq, on or before November 26, 2008, the Company's specific plan to achieve and sustain compliance with all of The Nasdaq Capital Market listing requirements, including the time frame for completion of the plan.

About Pharmos Corporation

Pharmos discovers and develops novel therapeutics to treat a range of indications including specific diseases of the nervous system such as disorders of the brain-gut axis (GUIBS), pain/inflammation, and autoimmune disorders. The Company's lead product in development, dextofisopam, is undergoing Phase 2b testing in IBS patients. Dextofisopam has completed a Phase 2a IBS study in which it demonstrated a statistically significant effect compared to placebo on the primary efficacy endpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies targeting pain, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and other disorders. Pharmos is also working to commercialize its proprietary NanoEmulsion drug delivery system, which is in clinical-stage development for topical application of analgesic and anti-inflammatory agents.

Safe Harbor Statement

Statements made in this press release related to the business outlook and future financial performance of Pharmos, to the prospective market penetration of its drug products, to the development and commercialization of its pipeline products and to its expectations in connection with any future event, condition, performance or other matter, are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause results to differ materially from those set forth in these statements. Additional economic, competitive, governmental, technological, marketing and other factors identified in Pharmos' filings with the Securities and Exchange Commission could affect such results.


'/>"/>
SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmos Restructures Operations in Israel
2. Pharmos Corporation Reports 2007 Fourth Quarter and Year-end Results
3. Pharmos Corporation Reports 2008 Third Quarter Results
4. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
5. Brooke Franchise Corporation Announces Selected July Results
6. MedThink Communications Retained by NanoBio Corporation
7. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
8. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
9. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
10. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
11. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., one of ... the newly designed, innovative shoulder wrap. The newly designed shoulder wrap has ... injured arm and shoulder to promote faster healing. It is highly recommended for ...
(Date:2/9/2016)... ... 09, 2016 , ... United Methodist Communications collaborated with Chocolate ... animated video designed to prevent the next widespread Ebola outbreak from ... being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire and other African ...
(Date:2/9/2016)... ... February 09, 2016 , ... i2i Systems, an early innovator and ... data vendors in the latest KLAS report, Population Health Management 2015: How Far Can ... market for population health management (PHM). The latest KLAS Report, leveraging over 200 ...
(Date:2/9/2016)... Ashburn, VA (PRWEB) , ... February 09, 2016 ... ... ) Small Mammal Prize has officially been won. A team from 21st Century ... has discovered a way to preserve the delicate neural circuits of an intact ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... redesigned website, federallabs.org . The site houses a wealth of federal resources ... technologies through the process called technology transfer (T2). As a network of over ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
(Date:2/9/2016)... 9, 2016 The new report "Global Diagnostic Ultrasound Devices ... Consulting group reveals that global diagnostic ultrasound devices market was valued ... US$ 7,466.3 million by 2019 at a CAGR of 6.8% from ... ultrasound market has been analyzed for six geographies of ... Asia-Pacific , Latin America , ...
(Date:2/9/2016)... , Feb. 9, 2016 The leader ... that AcceleDent ® is the recipient of the ... category. An FDA-cleared, Class II medical device that speeds ... percent and relieves pain often associated with treatment, AcceleDent ... participated in the annual Orthotown survey of ...
Breaking Medicine Technology: